Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Short term Debt: 2018-2021

Historic Short term Debt for AC Immune (ACIU) over the last 2 years, with Dec 2021 value amounting to $21.5 million.

  • AC Immune's Short term Debt was N/A to $21.5 million in Q4 2021 from the same period last year, while for Dec 2021 it was $21.5 million, marking a year-over-year change of. This contributed to the annual value of $21.7 million for FY2021, which is N/A change from last year.
  • AC Immune's Short term Debt amounted to $21.5 million in Q4 2021, which was up 7,609.91% from -$285,714 recorded in Q3 2020.
  • AC Immune's Short term Debt's 5-year high stood at $21.5 million during Q4 2021, with a 5-year trough of -$285,714 in Q3 2020.
  • For the 3-year period, AC Immune's Short term Debt averaged around $2.7 million, with its median value being $333.55 (2019).
  • As far as peak fluctuations go, AC Immune's Short term Debt soared by 97.47% in 2019, and later plummeted by 84,383.01% in 2020.
  • AC Immune's Short term Debt (Quarterly) stood at $333,605 in 2018, then soared by 97.47% to $658,770 in 2019, then tumbled by 84,383.01% to -$285,714 in 2020, then reached $21.5 million in 2021.
  • Its Short term Debt was $21.5 million in Q4 2021, compared to -$285,714 in Q3 2020 and -$272,945 in Q2 2020.